Pathogenesis Sample Clauses

Pathogenesis related proteins from grapes Pathogenesis-related (PR) proteins are typically acidic, of low molecular mass and highly resistant to proteolytic degradation. They accumulate in berries and leaves of grapevines (Figure 5) in response to pathogen attack and are thought to contribute in resistance (Xxxxxxxxx et al. 1998). The type of tissue, developmental stage, and type of infecting pathogen were observed to vary the pattern of PR-protein expression (Xxxxx et al. 1997; Xxxxxxx et al. 1999; Xxxxxx et al. 2002). In grape berries, PR-protein levels are also produced constitutively as a normal part of the ripening process (Xxxxxxxx et al. 1997; Xxxxxxxxxx et al. 1997) and this has been a prophylactic measure against environmental stress and pathogen attack (Xxxxxx and Xxxxxxxx 2000). Chitinase and thaumatin-like proteins represent the predominant PR-proteins in grape berries. These two protein families account for half of the soluble protein in ripe grapes (Xxxxxx et al. 1998). Xxxxxx et al. (2002) showed that grapevine leaves and berries expressed polygalacturonase inhibitor proteins (PGIPs) in response to infection by B. cinerea. PGIPs are thought to contribute to disease resistance by inhibiting the degradation of the plant cell wall by fungal polygalacturonases. PR proteins can also be induced in leaves and berries as part of a defensive response to the classical PR protein gene-inducers (wounding, chemical elicitors, pathogen attack, or abiotic stress) by the expression of specific PR genes (Xxxxxx et al. 1999; Xxxxxxxx and Xxxxx 2000). These processes modulate the levels and proportions of the PR proteins in grapes, apparently depending on the factors like cultivar, region, climate, and agricultural practices (Xxxxxxxx et al. 2003).
AutoNDA by SimpleDocs
Pathogenesis. To investigate the pathogenesis of SLE and LN, we focused on DNA. First, we studied microchimerism (Mc), which is the presence of a small number of genetically distinct cells (of any type and originating from a different zygote) in an individual. Fetal Mc arises from fetal cells that enter the maternal circulation. We used differences in genetic polymorphisms between individuals to detect Mc. Second, we studied the contribution of known lupus susceptibility polymorphisms in familial lupus nephritis. Both of these approaches are discussed below. SLE
Pathogenesis. The prime target for inflammation in RA is the synovium, which when inflamed is termed synovitis. The synovium in a normal joint serves as an important source of nutrients for cartilage as cartilage itself has no blood supply. Another important function of the synovium is the production of hyaluronic acid, which acts as lubrication for the joint. Hyaluronic acid is present in small volumes in the normal joint and helps normal movement and function. The synovial cells also produce collagens and fibronectins which make up the structural framework of the synovial interstitium. In RA, the inflamed synovium produces larger quantities of synovial fluid, which clinically is seen as joint swelling or effusion and is one of the hallmarks of RA. The fluid is also less viscous than normal synovial fluid and contains high levels of inflammatory cells and other mediators of the inflammatory process. The lining of normal synovium is only a few cells thick (1-3), with few if any inflammatory cells, but in RA the lining becomes markedly hypertrophied, up to 8- 10 cells thick. Cells seen in the layer in RA are predominantly macrophages and fibroblasts. The layer below this, the subintimal layer, contains the blood vessels which supply the synovium and normally contains very few cells. However, in RA, this layer is heavily infiltrated with inflammatory cells, including T cells, B cells and macrophages. Accompanying this heavy infiltration is new blood vessel formation, called angiogenesis. The greatly hypertrophied synovium is also called pannus and it has almost tumour like qualities as it invades and erodes adjacent cartilage and bone, which leads to the erosions seen on x-ray. It is felt that T cells play a central role in the pathogenesis of RA, but other cells such as B cells, macrophages, fibroblasts and osteoclasts also play vital roles in the inflammatory process. [Xxxx et al. 2001] The first step in the inflammatory process in RA is the uptake of antigen by antigen presenting cells (APCs), which is then degraded into peptides which are inserted into the groove of HLA-DR molecules on the surface of the APCs and presented to CD4+ T cells. The antigens which trigger this process are unknown; they may be autoantigens, microbial antigens or other external antigens. The T cell receptor recognises the HLA-DR, antigenic peptide complex and through a series of molecular events and gene transcription the T cell becomes activated. [Xxxxxxx et al. 1993] In order for the T cell...
Pathogenesis. If PathoGenesis is responsible for causing any Non- ------------ conforming Finished Product, PathoGenesis will pay ALP the Processing Fees for both the Non-conforming Finished Product and the Finished Product.
Pathogenesis. During the Term and for five years thereafter, ------------ PathoGenesis will obtain and maintain comprehensive general liability insurance (including broad form general liability, completed operations and products liability, personal injury liability, blanket contractual liability and broad form property damage liability) with limits of not less than $5,000,000 combined single limit for bodily injury and property damage liability per occurrence and annual aggregate, containing a cross liability or severability of interests clause. During the Term, PathoGenesis will obtain and maintain worker's compensation insurance as required under applicable law and employer's liability insurance with a limit of not less than $1,000,000. With respect to such insurance coverage required under this section 10.5(b): (i) PathoGenesis will furnish ALP with certificates of insurance evidencing at least the required coverage as soon as practicable evidencing at least the required coverage as soon as practicable after the Effective Date and each anniversary of the Effective Date during the Term (and for five years thereafter if such coverage is then required hereunder); and (ii) all policies will include Provisions for at least 30 days prior written notice of any material change or cancellation (whether for non-payment or otherwise).
Pathogenesis. The pathogenesis and spectrum of disease in LF has developed in recent years. As a result of ultrasound studies, it is now understood that all patients have some underlying pathology [23], although not all will present with clinical pathology. The heterogeneity of pathology among patients is not well understood, although it is probably related to the immunology in each patient. Among asymptomatic microfilaria-positive individuals, hidden lymphatic damage has been found. As the microfilaremia levels decrease over time, patients transition to become acutely symptomatic experiencing acute adenolymphangitis (ADL) and acute filarial attacks (AFL). The interval between detective microfilaremia and symptoms is the clinical incubation period [24] which may vary between 2 and 10 years in an endemic community. Following the acute phase, many patients begin to show signs of chronic lymphedema, which may lead to advanced stages of elephantiasis. Tropical pulmonary eosinophilia is a rare outcome that involves paraoxysmal cough and wheezing, weight loss, low-grade fever, adenopathy, and pronounced blood eosinophilia (>3000 eosinophils (White blood cells)/μl) [2]. Tropical pulmonary eosinophilia is a result of intense immune response to circulating microfilaria. Persons with this outcome will have low mf levels, but will be antigen and antibody positive. In most cases, there are restrictive pulmonary function abnormalities. If not treated with DEC, the disease may progress to chronic restrictive lung disease with interstitial fibrosis.
Pathogenesis. The presence of placental vascular anastomoses is a conditio sine qua non for the development of TTTS. Injection studies of twin placentas have shown that such anastomoses are almost invariably present in monochorionic twins and extremely rare in dichorionic twins5. Three types of anastomoses have been documented: from artery to artery, from vein to vein and from artery to vein. Arterio-venous anastomoses are unidirectional and are referred to as “deep” anastomoses since they proceed through a shared placental cotyledon, whereas arterio-arterial and xxxx-venous anastomoses are bi-directional and are referred to as “superficial” since they lie on the chorionic plate (Figure 1). Injection studies of monochorionic placentas have demonstrated that arterio-arterial, arterio-venous and xxxx-venous anastomoses are present in 80%, 95% and 20% of monochorionic placentas, respectively 60-62. The presence of at least one arterio-venous anastomosis has been shown to be essential for the development of chronic TTTS26;61-63. According to the classic pathophysiological concept, chronic TTTS is caused by net imbalance of blood flow between the twins due to arterio-venous anastomoses7;8. Blood from one twin (the donor) is pumped through an artery into the shared placental cotyledon and then drained through a vein into the circulation of the other twin (the recipient). Unless blood is pumped back from the recipient to the donor through oppositely directed FIGURE 1 Placenta injection study with colored dye from a monochorionic twin gestation without chronic twin-to- twin transfusion syndrome delivered after 38 weeks of gestation. Arteries are injected with dark-blue dye and veins with orange dye. The arrow at the bottom of the picture indicates an arterio-arterial anastomosis. An arterio-venous anastomosis from twin 2 to twin 1 is pointed out in the center of the picture, whereas an arterio-venous anastomosis from twin 1 to twin 2 is indicated at the top of the picture. Twin 2 has a velamentous cord insertion. deep arterio-venous anastomoses or through superficial anastosmoses, an imbalance of blood volumes occurs, gradually leading to the development of chronic TTTS. The presence of arterio-arterial anastomoses in particular is thought to give some protection against the development of chronic TTTS by compensating for the circulatory imbalance caused by the uni-directional arterio-venous anastomoses7;8. Various studies have demonstrated that these bi-directional arterio-art...
AutoNDA by SimpleDocs

Related to Pathogenesis

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Formation; Composition Within […***…] days after the Effective Date, the Parties shall establish a committee to oversee Development of Licensed Product(s) in the Territory in accordance with the Development Plan(s) for the same and to coordinate the Development activities of the Parties, and review and discuss the Development and Manufacture of Licensed Compound and Licensed Products (the “JDC”). Each Party shall initially appoint three (3) representatives to the JDC, with each representative having knowledge and expertise in the development of compounds and products similar to the Licensed Products and having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC’s responsibilities. The JDC may change its size from time to time if agreed by consensus among its members, provided that the JDC shall consist at all times of an equal number of representatives of each of Galapagos and Gilead. Each Party may replace its JDC representatives at any time upon written notice to the other Party. The JDC may invite non-members to participate in the discussions and meetings of the JDC, provided that such participants shall have no voting authority at the JDC. The JDC shall have a chairperson, who shall serve for a term of one (1) year, and who shall be selected alternately, on an annual basis, by Galapagos or Gilead. The initial chairperson shall be selected by […***…]. The role of the chairperson shall be to convene and preside at meetings of the JDC and to ensure the preparation of minutes, but the chairperson shall have no additional powers or rights beyond those held by the other JDC representatives.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Third Party Technology The Company makes use of third party technology to collect information required for traffic measurement, research, and analytics. Use of third party technology entails data collection. We therefore would like to inform clients the Company enables third parties to place or read cookies located on the browsers of users entering the Company’s domain. Said third parties may also use web beacons to collect information through advertising located on the Company’s web site. Please note that you may change your browser settings to refuse or disable Local Shared Objects and similar technologies; however, by doing so you may be disabling some of the functionality of Company’s services.

  • Products Products available under this Contract are limited to Software, including Software as a Service, products and related products as specified in Appendix C, Pricing Index. Vendor may incorporate changes to their product offering; however, any changes must be within the scope of products awarded based on the posting described in Section 1.B above. Vendor may not add a manufacturer’s product line which was not included in the Vendor’s response to the solicitation described in Section 1.B above.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

Time is Money Join Law Insider Premium to draft better contracts faster.